Retinal vein occlusion

Roche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO...

FDA Granted Fast Track Designation to Oncternal Therapeutics’s ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer On Oct. 26, 2023, Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting andr...

Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market. T...

Retinal vein occlusion (RVO) is the second most common vision-threatening disorder that happens due to retinal vascular disease. If left untreated, RVO can result in vision impairment and a significant amount of other ocular complications. Any kind of blockage in the vein of the eye that carries blood from the reti...